Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

Abstract RNA plays a central role in the expression of all genes. Because any sequence within RNA can be recognized by complementary base pairing, synthetic oligonucleotides and oligonucleotide mimics offer a general strategy for controlling processes that affect disease. The two primary antisense approaches for regulating expression through recognition of cellular RNAs are single-stranded antisense oligonucleotides and duplex RNAs. This review will discuss the chemical modifications and molecular mechanisms that make synthetic nucleic acid drugs possible. Lessons learned from recent clinical trials will be summarized. Ongoing clinical trials are likely to decisively test the adequacy of our current generation of antisense nucleic acid technologies and highlight areas where more basic research is needed.

[1]  C. Sheridan.  With Alnylam's amyloidosis success, RNAi approval hopes soar , 2017, Nature Biotechnology.

[2]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[3]  A. T. van der Ploeg,et al.  The Dilemma of Two Innovative Therapies for Spinal Muscular Atrophy. , 2017, The New England journal of medicine.

[4]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[5]  T. P. Prakash,et al.  Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes , 2017, Nucleic acids research.

[6]  S. Tabrizi,et al.  Therapies targeting DNA and RNA in Huntington's disease , 2017, The Lancet Neurology.

[7]  Adriane N. Irwin,et al.  Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns—an Alternative Viewpoint , 2017, Pharmacotherapy.

[8]  Naoki Iwamoto,et al.  Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides , 2017, Nature Biotechnology.

[9]  A. Akinc,et al.  Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy , 2017, The New England journal of medicine.

[10]  Ž. Reiner.  Hypertriglyceridaemia and risk of coronary artery disease , 2017, Nature Reviews Cardiology.

[11]  D. Rubinsztein,et al.  Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. , 2017, Cold Spring Harbor perspectives in medicine.

[12]  S. Crooke,et al.  The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials , 2017, Nucleic acid therapeutics.

[13]  E. Mercuri,et al.  Therapeutic approaches for spinal muscular atrophy (SMA) , 2017, Gene Therapy.

[14]  Yajnavalka Banerjee,et al.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. , 2017, The New England journal of medicine.

[15]  C. Stein,et al.  FDA-Approved Oligonucleotide Therapies in 2017. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  T. Papoian,et al.  Safety of antisense oligonucleotide and siRNA-based therapeutics. , 2017, Drug discovery today.

[17]  S. Tabrizi,et al.  Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells , 2017, Scientific Reports.

[18]  A. Aartsma-Rus.  FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. , 2017, Nucleic acid therapeutics.

[19]  S. Crooke.  Molecular Mechanisms of Antisense Oligonucleotides , 2017, Nucleic acid therapeutics.

[20]  T. CrookeStanley.  Molecular Mechanisms of Antisense Oligonucleotides. , 2017 .

[21]  P. McCullough,et al.  Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia. , 2017, Reviews in cardiovascular medicine.

[22]  Lawrence A Leiter,et al.  Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol , 2017, The New England journal of medicine.

[23]  N. Goemans,et al.  Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids , 2017, Neuromuscular Disorders.

[24]  K. Lim,et al.  Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.

[25]  Stanley T Crooke,et al.  Cellular uptake and trafficking of antisense oligonucleotides , 2017, Nature Biotechnology.

[26]  anastasia. khvorova,et al.  The chemical evolution of oligonucleotide therapies of clinical utility , 2017, Nature Biotechnology.

[27]  S. Dowdy.  Overcoming cellular barriers for RNA therapeutics , 2017, Nature Biotechnology.

[28]  David R Corey,et al.  Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy , 2017, Nature Neuroscience.

[29]  A. J. Donner,et al.  Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor , 2017, Nucleic acids research.

[30]  A. Krieg,et al.  FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga , 2017, Nucleic acid therapeutics.

[31]  B. Bettencourt,et al.  Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  A. Khvorova.  Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. , 2017, The New England journal of medicine.

[33]  R. Califf,et al.  Regarding “Eteplirsen for the treatment of Duchenne muscular dystrophy” , 2017, Annals of neurology.

[34]  A. Kesselheim,et al.  Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. , 2016, JAMA.

[35]  Yuanyu Huang.  Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics , 2016, Molecular therapy. Nucleic acids.

[36]  K. Garber.  Alnylam terminates revusiran program, stock plunges , 2016, Nature Biotechnology.

[37]  Lawrence M. Lifshitz,et al.  Visualization of self-delivering hydrophobically modified siRNA cellular internalization , 2016, Nucleic acids research.

[38]  S. Crooke,et al.  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.

[39]  J. Rossi,et al.  Aptamers as targeted therapeutics: current potential and challenges , 2016, Nature Reviews Drug Discovery.

[40]  M. Hope,et al.  Pieter Cullis’ quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA? , 2016, Journal of drug targeting.

[41]  A. Khvorova,et al.  Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain , 2016, Molecular therapy. Nucleic acids.

[42]  D. Corey,et al.  Non-coding RNAs as drug targets , 2016, Nature Reviews Drug Discovery.

[43]  J. Kastelein,et al.  Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. , 2016, Journal of clinical lipidology.

[44]  M. Benson,et al.  Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[45]  H. Schmidt.  Therapeutic oligonucleotides targeting liver disease , 2016 .

[46]  Mallory A. Havens,et al.  Splice-switching antisense oligonucleotides as therapeutic drugs , 2016, Nucleic acids research.

[47]  Richard G. Lee,et al.  Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes , 2016, Diabetes Care.

[48]  R. Juliano,et al.  The delivery of therapeutic oligonucleotides , 2016, Nucleic acids research.

[49]  J. Witztum,et al.  Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1 , 2016, Journal of Lipid Research.

[50]  A. Khandji,et al.  Intrathecal Injections in Children With Spinal Muscular Atrophy , 2016, Journal of child neurology.

[51]  N. Kootstra,et al.  MIRAVIRSEN DOSING IN CHRONIC HEPATITIS C PATIENTS RESULTS IN DECREASED MICRORNA-122 LEVEL WITHOUT AFFECTING OTHER MICRORNA’S IN PLASMA , 2017 .

[52]  A. Tefferi,et al.  Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis , 2015, Blood Cancer Journal.

[53]  A. J. Donner,et al.  CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation , 2015, Molecular therapy. Nucleic acids.

[54]  J. Nemunaitis,et al.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer , 2015, Science Translational Medicine.

[55]  M. Behlke,et al.  Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides , 2015, Nucleic acids research.

[56]  Christopher E. Hart,et al.  Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts , 2015, Nucleic acids research.

[57]  B. Byrne,et al.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy , 2015, Annals of neurology.

[58]  S. Milstein,et al.  Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification , 2015, Molecular therapy. Nucleic acids.

[59]  J. Watts,et al.  Oligonucleotide therapeutics: chemistry, delivery and clinical progress. , 2015, Future medicinal chemistry.

[60]  S. Crooke,et al.  The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA , 2015, Nucleic acids research.

[61]  C. Niemietz,et al.  Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis , 2015, Molecules.

[62]  B. Nicke,et al.  Deciphering Seed Sequence Based Off-Target Effects in a Large-Scale RNAi Reporter Screen for E-Cadherin Expression , 2015, PloS one.

[63]  B. Bettencourt,et al.  Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study , 2015, Orphanet Journal of Rare Diseases.

[64]  R. Laborde,et al.  A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. , 2015, The New England journal of medicine.

[65]  M. McDevitt,et al.  Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. , 2015, The New England journal of medicine.

[66]  G. Comi,et al.  Spinal muscular atrophy—recent therapeutic advances for an old challenge , 2015, Nature Reviews Neurology.

[67]  P. Devarajan,et al.  Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[68]  S. Crooke,et al.  Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B , 2015, Clinical Pharmacokinetics.

[69]  Naoki Nakagawa,et al.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. , 2015, The Journal of clinical investigation.

[70]  Kendall S. Frazier,et al.  Antisense Oligonucleotide Therapies , 2015, Toxicologic pathology.

[71]  Fritz Eckstein,et al.  Phosphorothioates, essential components of therapeutic oligonucleotides. , 2014, Nucleic acid therapeutics.

[72]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[73]  L. van Doorn,et al.  In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122 , 2014, Antimicrobial Agents and Chemotherapy.

[74]  S. Freier,et al.  Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients , 2014, PloS one.

[75]  D. Meller,et al.  Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study. , 2014, Ophthalmology.

[76]  Zhonghan Li,et al.  Therapeutic targeting of microRNAs: current status and future challenges , 2014, Nature Reviews Drug Discovery.

[77]  Shuling Guo,et al.  Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice , 2014, Nucleic acids research.

[78]  R. Desnick,et al.  RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice , 2014, Proceedings of the National Academy of Sciences.

[79]  D. Rader,et al.  Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. , 2014, Circulation.

[80]  P. Boisguérin,et al.  Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells , 2013, Nucleic acids research.

[81]  K. Fitzgerald,et al.  Liver as a target for oligonucleotide therapeutics. , 2013, Journal of hepatology.

[82]  M. Stoffel,et al.  Miravirsen (SPC3649) can inhibit the biogenesis of miR-122 , 2013, Nucleic acids research.

[83]  G. Meister.  Argonaute proteins: functional insights and emerging roles , 2013, Nature Reviews Genetics.

[84]  S. Kauppinen,et al.  Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.

[85]  T. Abramova.  Frontiers and Approaches to Chemical Synthesis of Oligodeoxyribonucleotides , 2013, Molecules.

[86]  A. Levin,et al.  Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. , 2012, Toxicology.

[87]  A. Krainer,et al.  Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides , 2012, Open Biology.

[88]  Stanley T. Crooke,et al.  Single-Stranded siRNAs Activate RNAi in Animals , 2012, Cell.

[89]  Jing Liu,et al.  Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression , 2012, Cell.

[90]  G. Deleavey,et al.  Designing chemically modified oligonucleotides for targeted gene silencing. , 2012, Chemistry & biology.

[91]  S. Hammond,et al.  Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment , 2012, Molecular therapy. Nucleic acids.

[92]  L. Shihabuddin,et al.  Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis , 2012, Neuron.

[93]  Satyakam Bhagavati,et al.  Exon-skipping therapy for Duchenne muscular dystrophy , 2012, The Lancet.

[94]  D. Corey,et al.  Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing , 2011, Nucleic acids research.

[95]  J. Shay,et al.  Targeting telomerase-expressing cancer cells , 2011, Journal of cellular and molecular medicine.

[96]  D. Corey,et al.  Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. , 2010, Chemistry & biology.

[97]  Eric B. Roesch,et al.  Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. , 2010, Biochemistry.

[98]  C. Noe,et al.  Off‐Target Effects Related to the Phosphorothioate Modification of Nucleic Acids , 2010, ChemMedChem.

[99]  M. Lindholm,et al.  Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates , 2010, Nucleic acids research.

[100]  L. Fadiga,et al.  Active perception: sensorimotor circuits as a cortical basis for language , 2010, Nature Reviews Neuroscience.

[101]  T. P. Prakash,et al.  Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'O-ethyl nucleic acid analogues. , 2010, The Journal of organic chemistry.

[102]  D. Corey.  Telomeres and telomerase: from discovery to clinical trials. , 2009, Chemistry & biology.

[103]  H. Soifer,et al.  Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents , 2009, Nucleic acids research.

[104]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[105]  B. Landwehrmeyer,et al.  Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients , 2009, Current Biology.

[106]  I. MacRae,et al.  The RNA-induced Silencing Complex: A Versatile Gene-silencing Machine* , 2009, The Journal of Biological Chemistry.

[107]  G. van Ommen,et al.  Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations , 2009, Human mutation.

[108]  G. Bonvento,et al.  Sustained effects of nonallele‐specific Huntingtin silencing , 2009, Annals of neurology.

[109]  T. Tuschl,et al.  Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex , 2008, Nature.

[110]  A. Schneeweiss,et al.  Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[111]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[112]  Brenda F Baker,et al.  Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon , 2007, PLoS biology.

[113]  J. Kastelein,et al.  Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B , 2006, Circulation.

[114]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[115]  A. Khvorova,et al.  Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature , 2006, Cancer Gene Therapy.

[116]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[117]  M. Graham,et al.  An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M400492-JLR200 , 2005, Journal of Lipid Research.

[118]  A. Khvorova,et al.  Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells , 2004, Clinical Cancer Research.

[119]  K. Tanabe,et al.  Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy , 2004, Cancer.

[120]  J. M. Thomson,et al.  Argonaute2 Is the Catalytic Engine of Mammalian RNAi , 2004, Science.

[121]  D. Corey,et al.  Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2'-O-methoxyethyl oligonucleotides. , 2002, Journal of medicinal chemistry.

[122]  P. Griffiths,et al.  Fomivirsen for the treatment of cytomegalovirus retinitis. , 2002, American journal of ophthalmology.

[123]  A. Krainer,et al.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.

[124]  Sharlene R. Lim,et al.  Modulation of Survival Motor Neuron Pre-mRNA Splicing by Inhibition of Alternative 3′ Splice Site Pairing* , 2001, The Journal of Biological Chemistry.

[125]  C. Stein.  The experimental use of antisense oligonucleotides: a guide for the perplexed. , 2001, The Journal of clinical investigation.

[126]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[127]  C. Mann,et al.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[128]  S. Crooke.  Evaluating the mechanism of action of antiproliferative antisense drugs. , 2000, Antisense & nucleic acid drug development.

[129]  M. Manoharan.  2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. , 1999, Biochimica et biophysica acta.

[130]  D. Corey,et al.  Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[131]  C. A. Stein,et al.  Keeping the biotechnology of antisense in context , 1999, Nature Biotechnology.

[132]  M. Grunwalde.  Behind the mask , 1999, Trends in Cognitive Sciences.

[133]  Y. Hari,et al.  Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2'-O,4'- C-methyleneribonucleosides , 1998 .

[134]  Poul Nielsen,et al.  LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition , 1998 .

[135]  D. Coen,et al.  Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922) , 1998, Antimicrobial Agents and Chemotherapy.

[136]  W. Goebel,et al.  Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes , 1998, Nature Biotechnology.

[137]  Z. Dominski,et al.  Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[138]  P. D. Cook,et al.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.

[139]  H. Nakamura,et al.  How does RNase H recognize a DNA.RNA hybrid? , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[140]  T. Hunt,et al.  The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. , 1986, Nucleic acids research.

[141]  D. Sah,et al.  Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets , 2009, Neuropsychopharmacology.

[142]  David R Corey,et al.  RNA learns from antisense. , 2007, Nature chemical biology.

[143]  S. P. Westphal.  Behind the mask , 2003 .

[144]  Richard S Geary,et al.  Fomivirsen: clinical pharmacology and potential drug interactions. , 2002, Clinical pharmacokinetics.

[145]  D. Corey,et al.  Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. , 2001, Chemistry & biology.

[146]  N M Dean,et al.  Sensible use of antisense: how to use oligonucleotides as research tools. , 2000, Trends in pharmacological sciences.

[147]  S. Crooke.  Proof of mechanism of antisense drugs. , 1996, Antisense & nucleic acid drug development.

[148]  P. Iversen,et al.  Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. , 1995, Antisense research and development.

[149]  A. Krieg,et al.  Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. , 1994, Antisense research and development.

[150]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.